5 Pharmaceutical Stocks to Buy Based on Billionaire Ken Griffin’s Portfolio

In this article, we discuss the top 5 pharmaceutical stocks to buy based on billionaire Ken Griffin’s portfolio. If you want our detailed analysis of the pharmaceutical industry, go directly to 10 Pharmaceutical Stocks to Buy Based on Billionaire Ken Griffin’s Portfolio. 

5. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Citadel Investment Group’s Stake Value: $198,174,000

Percentage of Citadel Investment Group’s 13F Portfolio: 0.04%

Number of Hedge Fund Holders: 60

Headquartered in Dublin, Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is a global biotechnology company that is engaged in the research and development of medicines that treat rare and rheumatic diseases. Ken Griffin, in Q3 2021, increased his position in Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) by 5%, holding 1.80 million shares of the company worth $198.1 million, representing 0.04% of the billionaire’s Q3 securities. 

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) on November 3 announced earnings for the third quarter. EPS in the period totaled $1.75, exceeding estimates by $0.21. The quarterly revenue increased almost 63% year-over-year, coming in at $1.04 billion, beating estimates by $57.5 million. 

On November 18, Goldman Sachs analyst Madhu Kumar upgraded Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) to Buy from Neutral with a $168 price target, observing that the company’s top medical assets are major value and revenue drivers.

Kurt Von Emster’s VenBio Select Advisor is the leading stakeholder of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), with 9 million shares worth $985.86 million. Overall, 60 hedge funds in the database of Insider Monkey were long Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in the third quarter, with total stakes amounting to $4.57 million. 

Here is what Carillon Tower Advisers has to say about Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in their Q1 2021 investor letter:

“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product Tepezza, which is used in the treatment of thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”